Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. https://doi.org/10.3322/caac.21492.

Article  PubMed  Google Scholar 

du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d’Investigateurs Nationaux Pour les Etudes des Cancers de l’Ovaire (GINECO). Cancer. 2009;115:1234–44. https://doi.org/10.1002/cncr.24149.

Article  CAS  PubMed  Google Scholar 

Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9:167–81. https://doi.org/10.1038/nrc2583.

Article  CAS  PubMed  Google Scholar 

Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer. Obstet Gynecol Surv. 2014;69:402–4. https://doi.org/10.1200/JCO.2013.51.4489.

Article  CAS  Google Scholar 

Stephanie L, Charlie G, Ignace V, Oza AM. Epithelial ovarian cancer. Lancet (London, England). 2019;393:1240–53. https://doi.org/10.1016/S0140-6736(18)32552-2.

Article  Google Scholar 

Bois AD, Vergote I, Ferron G, Reuss A, Sehouli J. Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20. J Clin Oncol. 2017;35:5501–5501. https://doi.org/10.1200/JCO.2017.35.15_suppl.5501.

Article  Google Scholar 

Bois AD, Sehouli J, Vergote I, Ferron G, Harter P. Randomized phase III study to evaluate the impact of secondary cytoreductive surgery in recurrent ovarian cancer: final analysis of AGO DESKTOP III/ENGOT-ov20. J Clin Oncol. 2020;38:6000–6000. https://doi.org/10.1200/JCO.2020.38.15_suppl.6000.

Article  Google Scholar 

Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:779–91. https://doi.org/10.1016/S1470-2045(17)30279-6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shi T, Zhu J, Feng Y, Tu D, Zang R. Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:439–49. https://doi.org/10.1016/S1470-2045(21)00006-1.

Article  CAS  PubMed  Google Scholar 

Petrillo M, Anchora LP, Tortorella L, Fanfani F, Gallotta V, Pacciani M, et al. Secondary cytoreductive surgery in patients with isolated platinum-resistant recurrent ovarian cancer: a retrospective analysis. Gynecol Oncol. 2014;134:257–61. https://doi.org/10.1016/j.ygyno.2014.05.029.

Article  CAS  PubMed  Google Scholar 

Musella A, Marchetti C, Palaia I, Perniola G, Giorgini M, Lecce F, et al. Secondary cytoreduction in platinum-resistant recurrent ovarian cancer: a single-institution experience. Ann Surg Oncol. 2015;22:4211–6. https://doi.org/10.1245/s10434-015-4523-2.

Article  CAS  PubMed  Google Scholar 

Tuninetti V, Di Napoli M, Ghisoni E, Maggiorotto F, Robella M, Scotto G, et al. Cytoreductive surgery for heavily pre-treated, platinum-resistant epithelial ovarian carcinoma: a two-center retrospective experience. Cancers. 2020;12:2239. https://doi.org/10.3390/cancers12082239.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13:1702–10. https://doi.org/10.1245/s10434-006-9058-0.

Article  PubMed  Google Scholar 

Tian WJ, Chi DS, Sehouli J, Tropé CG, Jiang R, Ayhan A, et al. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection. Ann Surg Oncol. 2012;19:597–604. https://doi.org/10.1245/s10434-011-1873-2.

Article  PubMed  Google Scholar 

Laga T, Lambrechts S, Laenen A, Van NE, Han SN, Vergote I. Positive DESKTOP and Tian Scores systems are adequate to predict optimal (R0) secondary debulking surgery in ovarian cancer, but a negative score does not preclude secondary surgery. Int J Gynecol Cancer. 2018;28:721–8. https://doi.org/10.1097/igc.0000000000001219.

Article  PubMed  Google Scholar 

Salani R, Santillan A, Zahurak ML, Giuntoli RL, Gardner GJ, Armstrong DK, et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer. 2007;109:685–91. https://doi.org/10.1002/cncr.22447.

Article  PubMed  Google Scholar 

Schorge JO, Wingo SN, Bhore R, Heffernan TP, Lea JS. Secondary cytoreductive surgery for recurrent platinum-sensitive ovarian cancer. Int J Gynecol Cancer. https://doi.org/10.1016/j.ijgo.2009.08.034.

Chi DS, McCaughty K, Diaz JP, Huh J, Schwabenbauer S, Hummer AJ, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933–9. https://doi.org/10.1002/cncr.21845.

Article  PubMed  Google Scholar 

Son JH, Lee J, Yum SH, Kim J, Kong TW, Chang SJ, et al. Simplified selection criteria for secondary cytoreductive surgery in recurrent ovarian cancer. Cancers. 2022;14. https://doi.org/10.3390/cancers14163987.

Conte C, Marchetti C, Loverro M, Giudice MT, Rosati A, Gallotta V, et al. Role of minimally invasive secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2023;33:137–44. https://doi.org/10.1136/ijgc-2022-003904.

Article  PubMed  Google Scholar 

Gronlund B, Lundvall L, Christensen IJ, Knudsen JB, Høgdall C. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol. 2005;31:67–73. https://doi.org/10.1016/j.ejso.2004.08.016.

Article  CAS  PubMed  Google Scholar 

Wilson MK, Pujade-Lauraine E, Aoki D, Mirza MR, Lorusso D, Oza AM, et al. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease. Ann Oncol. 2017;28:727–32. https://doi.org/10.1093/annonc/mdw663.

Article  CAS  PubMed  Google Scholar 

Tian WJ, Jiang R, Cheng X, Tang J, Xing Y, Zang RY. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1–1 cm after secondary cytoreduction. J Surg Oncol. 2010;101:244–50. https://doi.org/10.1002/jso.21491.

Article  PubMed  Google Scholar 

Onda T, Satoh T, Ogawa G, Saito T, Kasamatsu T, Nakanishi T, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial. Eur J Cancer. 2020;130:114–25. https://doi.org/10.1016/j.ejca.2020.02.020.

Article  CAS  PubMed  Google Scholar 

Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13. https://doi.org/10.1097/01.sla.0000133083.54934.ae.

Article  PubMed  PubMed Central  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. https://doi.org/10.1016/j.ejca.2008.10.026.

Article  CAS  PubMed  Google Scholar 

Norton L, Simon R. Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep. 1977;61:1307–17.

CAS  PubMed  Google Scholar 

Howard E, Skipper. Adjuvant chemotherapy. Cancer. 1978;41:936–40. https://doi.org/10.1002/1097-0142(197803)41:3%3c936::AID-CNCR2820410322%3e3.0.

Article  Google Scholar 

Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1978;63:1727–33.

Google Scholar 

Petrillo M, Fagotti A, Ferrandina G, Fanfani F, Costantini B, Vizzielli G, et al. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol. 2013;131:36–41. https://doi.org/10.1016/j.ygyno.2013.06.020.

Article  CAS  PubMed  Google Scholar 

Gallotta V, Bruno M, Conte C, Giudice MT, Davià F, Moro F, et al. Salvage lymphadenectomy in recurrent ovarian cancer patients: analysis of clinical outcome and BRCA1/2 gene mutational status. Eur J Surg Oncol. 2020;46:1327–33. https://doi.org/10.1016/j.ejso.2020.01.035.

Article  CAS  PubMed  Google Scholar 

Gallotta V, Conte C, D’Indinosante M, Capoluongo E, Minucci A, De Rose AM, et al. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases. Eur J Surg Oncol. 2019;45:2096–102. https://doi.org/10.1016/j.ejso.2019.06.023.

Article  PubMed  Google Scholar 

Paik ES, Lee YY, Kim TJ, Choi CH, Lee JW, Kim BG, et al. Feasibility of laparoscopic cytoreduction in patients with localized recurrent epithelial ovarian cancer. J Gynecol Oncol. 2016;27: e24. https://doi.org/10.3802/jgo.2016.27.e24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gallotta V, Conte C, Giudice MT, Nero C, Vizzielli G, Gueli Alletti S, et al. Secondary laparoscopic cytoreduction in recurrent ovarian cancer: a large, single-institution experience. J Minim Invasive Gynecol. 2018;25:644–50. https://doi.org/10.1016/j.jmig.2017.10.024.

Article  PubMed  Google Scholar 

Escobar PF, Levinson KL, Magrina J, Martino MA, Barakat RR, Fader AN, et al. Feasibility and perioperative outcomes of robotic-assisted surgery in the management of recurrent ovarian cancer: a multi-institutional study. Gynecol Oncol. 2014;134:253–6. https://doi.org/10.1016/j.ygyno.2014.05.007.

Article  PubMed